Angelalign Technology Inc. (HK:6699)
:6699
Want to see HK:6699 full AI Analyst Report?
Top Page
Angelalign Technology Inc.
(6699)
Select Model
Select Model
Rating:66Neutral
Price Target:
HK$97.00
▲(7.48% Upside)
Action:ReiteratedDate:03/31/26
The score is driven primarily by solid financial strength (low leverage) and a meaningful latest-year improvement in cash flow, which reduces downside financial risk. This is tempered by inconsistent profitability over recent years and a high P/E valuation, while technical indicators are constructive but not strongly bullish due to negative MACD.
Positive Factors
Conservative Balance Sheet
Very low leverage gives durable financial flexibility, lowering solvency and refinancing risk. Over the next 2–6 months this supports continued investment in sales, R&D and working-capital needs without needing emergency financing, increasing resilience to cyclical dips.
Negative Factors
Volatile Profitability
Wide margin swings reduce earnings predictability and complicate planning for reinvestment or shareholder returns. Structural margin pressure or cost variability could persist, making multi-quarter profitability recovery uncertain and raising execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage gives durable financial flexibility, lowering solvency and refinancing risk. Over the next 2–6 months this supports continued investment in sales, R&D and working-capital needs without needing emergency financing, increasing resilience to cyclical dips.
Read all positive factors
Angelalign Technology Inc. (6699) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$15.34B
Dividend YieldN/A
Average Volume (3M)742.42K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees3,576
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.63
Shares Outstanding170,896,380
10 Day Avg. Volume518,175
30 Day Avg. Volume742,423
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)2.59
Price to Sales (P/S)3.49
P/FCF Ratio17.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$94.88Price Target Upside5.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.18
Revenue Forecast (FY)HK$439.88M
Angelalign Technology Inc. Business Overview & Revenue Model
Company Description
Angelalign Technology Inc., an investment holding company, engages in the research and development, manufacture, and marketing of clear aligner treatment solutions in China. Its products include Angel Aligner Pro and Angel Aligner Classic, which a...
How the Company Makes Money
Angelalign primarily makes money by selling clear aligner orthodontic treatment solutions to dental clinics and orthodontists. Revenue is generated from providing sets of customized clear aligners for patients and associated orthodontic product/se...
Angelalign Technology Inc. Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
86
Very Positive
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.23B | 2.59B | 1.96B | 1.48B | 1.27B | 1.27B |
| Gross Profit | 1.39B | 1.60B | 1.23B | 920.71M | 785.69M | 826.65M |
| EBITDA | 177.56M | 293.27M | 77.34M | 154.39M | 318.65M | 372.47M |
| Net Income | 169.84M | 199.13M | 88.42M | 53.48M | 213.78M | 285.85M |
Balance Sheet | ||||||
| Total Assets | 5.59B | 5.34B | 4.95B | 4.76B | 4.49B | 4.14B |
| Cash, Cash Equivalents and Short-Term Investments | 3.49B | 3.00B | 436.83M | 3.44B | 3.65B | 3.63B |
| Total Debt | 651.66M | 16.30M | 14.48M | 65.28M | 28.20M | 30.29M |
| Total Liabilities | 2.14B | 1.82B | 1.44B | 1.35B | 884.01M | 826.11M |
| Stockholders Equity | 3.41B | 3.49B | 3.46B | 3.34B | 3.61B | 3.32B |
Cash Flow | ||||||
| Free Cash Flow | 166.46M | 523.39M | -76.78M | 51.28M | 51.48M | 241.95M |
| Operating Cash Flow | 376.79M | 712.07M | 123.48M | 165.87M | 146.87M | 441.71M |
| Investing Cash Flow | -439.06M | -1.26B | -138.82M | -981.71M | -159.77M | -182.05M |
| Financing Cash Flow | -34.78M | -175.45M | -28.46M | -187.06M | -193.61M | 2.52B |
Angelalign Technology Inc. Technical Analysis
Positive
90.25
Price Trends
74.04
Positive
68.81
Positive
66.02
Positive
Market Momentum
4.93
Negative
79.46
Negative
92.10
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6699, the sentiment is Positive. The current price of 90.25 is above the 20-day moving average (MA) of 76.23, above the 50-day MA of 74.04, and above the 200-day MA of 66.02, indicating a bullish trend. The MACD of 4.93 indicates Negative momentum. The RSI at 79.46 is Negative, neither overbought nor oversold. The STOCH value of 92.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6699.
Angelalign Technology Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$5.68B | 8.36 | 16.76% | 3.65% | 11.07% | 48.01% | |
72 Outperform | HK$25.88B | 20.07 | 21.02% | 0.63% | 6.10% | 16.67% | |
69 Neutral | HK$8.26B | 20.75 | 11.20% | ― | 25.24% | 7.29% | |
68 Neutral | HK$16.24B | 13.02 | 6.64% | 4.58% | 2.34% | -22.13% | |
66 Neutral | HK$15.34B | ― | 4.03% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6699
Angelalign Technology Inc.
87.15
39.14
81.52%
HK:1066
Shandong Weigao Group Medical Polymer Co
3.50
-1.97
-35.99%
HK:3600
Modern Dental Group Limited
6.08
2.08
52.11%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
38.66
12.16
45.89%
HK:2276
Shanghai Conant Optical Co. Ltd. Class H
48.60
24.96
105.58%
Angelalign Technology Inc. Corporate Events
Angelalign sets 2026 AGM to approve 2025 results and share issuance mandate
Apr 23, 2026
Angelalign Technology Inc. has called its annual general meeting for 9:00 a.m. on May 19, 2026, in Shanghai, where shareholders will review the audited financial statements and directors’ and auditor’s reports for the year ended Decemb...
Angelalign Elevates Chairman Feng Dai to Executive Role as Board Reshapes for Global Push
Apr 23, 2026
Angelalign Technology has re-designated long-serving board chairman Feng Dai from non-executive to executive director, effective 23 April 2026, positioning him as executive chairman with primary responsibility for strategy, corporate governance, r...
Angelalign Sets Out Board Composition and Governance Committee Roles
Apr 23, 2026
Angelalign Technology Inc. has disclosed the current composition of its board of directors, detailing a mix of executive and independent non-executive directors and formalising their respective roles. The move clarifies the company’s governa...
Angelalign grants RSUs to 51 employees under post-IPO incentive scheme
Mar 30, 2026
Angelalign Technology has granted 123,753 restricted share units to 51 group employees under its post-IPO RSU scheme, with no purchase price and no performance targets attached. The awards, structured with multi-year vesting schedules and a clawba...
Angelalign Announces Special Cash Dividend of HKD 4.99 Per Share for 2025
Mar 27, 2026
Angelalign Technology Inc., a Hong Kong–listed provider of orthodontic and dental alignment products, focuses on clear aligner solutions for patients seeking modern orthodontic care in China and selected overseas markets. Its business model ...
Angelalign Declares HKD 0.48 Final Dividend for 2025 Financial Year
Mar 27, 2026
Angelalign Technology Inc. has proposed a final ordinary cash dividend of HKD 0.48 per share for the financial year ended 31 December 2025, underscoring its commitment to returning profits to shareholders. The dividend, subject to shareholder appr...
Angelalign Boosts Global Clear Aligner Growth and Profit in 2025
Mar 27, 2026
Angelalign Technology reported strong growth for 2025, driven by surging demand for its clear aligner treatments across both Chinese mainland and overseas markets. Case volume rose 48.1% to about 532,400, with global markets ex‑China up 82.1...
Angelalign forecasts sharp profit surge on clear aligner growth and operating leverage
Mar 3, 2026
Angelalign Technology has issued a positive profit alert, saying it expects net profit for 2025 to rise to between USD24 million and USD30 million, up 140% to 200% from USD10 million in 2024. The improvement is driven by stronger global demand for...
Angelalign Moves to Modernise Governance with New Memorandum and Articles
Mar 3, 2026
Angelalign Technology Inc. plans to amend its existing memorandum and articles of association and adopt a third amended and restated version, subject to shareholder approval at the upcoming annual general meeting. The changes aim to modernise corp...
Angelalign Sets March Board Meeting to Approve 2025 Annual Results
Feb 25, 2026
Angelalign Technology Inc. has scheduled a board meeting for March 27, 2026, to review and approve the group’s annual results for the financial year ended December 31, 2025, and to consider the publication of those results. The board will al...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.